Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer. November 5, 2026 When, where, and in whom does recurrence occur after radical cystectomy for ...

The 2026 ESMO annual meeting featured a prostate cancer proffered paper session and a discussant presentation by Dr. Nicholas van As discussing two abstracts “Perioperative apalutamide + ADT with ...

Nicholas James discusses STAMPEDE’s multi-arm, multi-stage design and the STAMPEDE-2 reboot. Following COVID-related delays, STAMPEDE-2 now runs two arms: one testing radiation to all visible lesions ...

Adaptive MR-guided whole-pelvic SBRT with or without focal intraprostatic lesion boost for high-risk localized prostate Cancer: Adverse events and longitudinal quality-of-life outcomes. November 2, ...

(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...

This was a retrospective, single-center study conducted at a tertiary referral center between 2007 and 2024. Patients who ...

The 2026 European Society for Medical Oncology (ESMO) Annual Congress held Poster 2279P - ERG-Dependent Prognostic Impact of ...

Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...

The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...

Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...

The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...